Key Highlights

  • Shares rose 2.20% in pre-market trading to $15.77, up from a prior close of $15.43, after closing the prior session up 29.12%
  • Phase 2 SANRECO trial of divesiran met its primary endpoint, with 88% of divesiran-treated patients achieving clinical response versus 19% for placebo
  • Both divesiran dose groups showed substantial efficacy, with a 93.8% response rate at the every-six-week dose and 81.3% at the every-twelve-week dose
  • Divesiran was observed to be well tolerated with no new safety findings
  • Phase 3 trial evaluating divesiran administered every twelve weeks versus placebo is anticipated to begin in the first half of 2027
  • Company separately commenced an underwritten public offering of approximately $150 million of American Depositary Shares
  • Market Capitalization stands at $729 million, with a 52-week range of $4.19 to $17.58

Shares Extend Gains Following Positive Phase 2 Data

Silence Therapeutics (NASDAQ:SLN) shares were trading at $15.77 in pre-market activity on August 11, 2026, up 2.20% from the prior close of $15.43, building on a 29.12% surge in the prior regular session after the company announced positive topline results from its Phase 2 SANRECO trial of divesiran in polycythemia vera.

The 36-week, randomized, double-blind, placebo-controlled trial evaluated divesiran administered subcutaneously either every six weeks or every twelve weeks in 48 phlebotomy-dependent patients with polycythemia vera. The trial met its primary endpoint, with 88% of divesiran-treated patients achieving clinical response compared to 19% for placebo, a placebo-adjusted response rate of 69%.

What Silence Therapeutics Does

Silence Therapeutics is a London, UK-based clinical-stage biotechnology company dedicated to transforming people's lives by silencing disease-causing genes through precision-engineered medicines. Leveraging its proprietary mRNAi GOLD platform, the company designs siRNA molecules that harness the body's natural RNA interference mechanism to precisely target and silence disease-associated genes in the liver, addressing high unmet medical needs in cardiovascular, hematological, and rare diseases.

The company's wholly owned pipeline includes zerlasiran for cardiovascular disease linked to elevated lipoprotein and divesiran for hematological conditions such as polycythemia vera, alongside SLN548 for complement-mediated diseases. Silence Therapeutics also maintains strategic collaborations with major partners including AstraZeneca (NASDAQ:AZN), Mallinckrodt, and Hansoh Pharmaceutical to further expand its siRNA therapeutic platform.

Dose-Response Data and Path to Phase 3

Both divesiran dose groups showed substantial primary endpoint efficacy, with a 93.8% response rate observed at the every-six-week dosing schedule and an 81.3% response rate at the every-twelve-week schedule, suggesting the therapy maintains strong efficacy even at a less frequent dosing interval. Divesiran was observed to be well tolerated across the trial, with no new safety findings reported.

Based on these results, the company said a Phase 3 trial evaluating divesiran administered every twelve weeks versus placebo is anticipated to initiate in the first half of 2027, positioning the less frequent dosing schedule as the lead candidate for late-stage development given its combination of strong efficacy and improved dosing convenience for patients.

Concurrent Public Offering

Separately, Silence Therapeutics commenced an underwritten public offering of approximately $150 million of American Depositary Shares, with each ADS representing three ordinary shares in the company. The company also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of ADSs offered. Jefferies (NYSE:JEF), Morgan Stanley (NYSE:MS), Cantor Fitzgerald, and William Blair are acting as joint book-running managers for the proposed offering, which is intended to support the company's continued clinical development programs, including the newly announced Phase 3 divesiran trial.

Conclusion

Silence Therapeutics' continued gains reflect strong investor confidence in the positive Phase 2 SANRECO trial results for divesiran, which met its primary endpoint with a wide Margin over placebo and showed durable efficacy even at a less frequent dosing schedule. With a Phase 3 trial now planned for the first half of 2027 and a concurrent capital raise to help fund the next stage of development, the company appears to be moving decisively to Capitalize on the positive data while it has strong market attention and improved access to capital.